A phase II trial comparing T‐DXd with chemotherapy in 125 patients with HER2‐positive advanced gastric cancer (vs. 62 patients receiving chemotherapy) revealed a significantly higher ORR with T‐DXd (51 vs. This evidence concerns the gene ERBB2 and gastric cancer.